Agenus (NASDAQ:AGEN) Downgraded to Hold Rating by Wall Street Zen

Agenus (NASDAQ:AGEN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. HC Wainwright raised their price objective on shares of Agenus from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Finally, Zacks Research lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $30.00.

Agenus Trading Up 0.2%

Shares of AGEN opened at $5.01 on Friday. The stock has a 50 day moving average of $3.44 and a 200 day moving average of $3.49. The company has a market capitalization of $208.62 million, a price-to-earnings ratio of 3.15 and a beta of 1.55. Agenus has a 12 month low of $2.71 and a 12 month high of $8.70.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing the consensus estimate of $2.10 by ($1.08). Agenus had a negative return on equity of 31.66% and a net margin of 50.49%.The business had revenue of $33.74 million during the quarter, compared to analysts’ expectations of $129.50 million. As a group, equities research analysts predict that Agenus will post 0.83 earnings per share for the current year.

Institutional Trading of Agenus

A number of institutional investors have recently modified their holdings of the business. EP Wealth Advisors LLC purchased a new stake in shares of Agenus during the fourth quarter worth $31,000. R Squared Ltd purchased a new position in shares of Agenus in the fourth quarter valued at $41,000. Redwood Family Wealth LLC purchased a new position in shares of Agenus in the fourth quarter valued at $44,000. Quadrature Capital Ltd bought a new stake in shares of Agenus during the 4th quarter valued at $54,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Agenus during the 3rd quarter valued at $54,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.